Temozolomide Accord Unia Europejska - angielski - EMA (European Medicines Agency)

temozolomide accord

accord healthcare s.l.u. - temozolomide - glioma; glioblastoma - antineoplastic agents - for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy (rt) and subsequently as monotherapy treatment.for the treatment of children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.

TEMACCORD Australia - angielski - Department of Health (Therapeutic Goods Administration)

temaccord

accord healthcare pty ltd - temozolomide, quantity: 250 mg - capsule, hard - excipient ingredients: gelatin; colloidal anhydrous silica; sodium starch glycollate; tartaric acid; stearic acid; lactose; purified water; titanium dioxide; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.,treatment of recurrence of anaplastic astrocytoma and glioblastoma multiforme following standard therapy.,temozolomide is also indicated as a first-line treatment for patients with advanced metastatic malignant melanoma.

TEMACCORD Australia - angielski - Department of Health (Therapeutic Goods Administration)

temaccord

accord healthcare pty ltd - temozolomide, quantity: 180 mg - capsule, hard - excipient ingredients: purified water; lactose; titanium dioxide; colloidal anhydrous silica; iron oxide yellow; gelatin; tartaric acid; stearic acid; sodium starch glycollate; iron oxide red; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.,treatment of recurrence of anaplastic astrocytoma and glioblastoma multiforme following standard therapy.,temozolomide is also indicated as a first-line treatment for patients with advanced metastatic malignant melanoma.

TEMACCORD Australia - angielski - Department of Health (Therapeutic Goods Administration)

temaccord

accord healthcare pty ltd - temozolomide, quantity: 140 mg - capsule, hard - excipient ingredients: gelatin; purified water; indigo carmine; colloidal anhydrous silica; stearic acid; titanium dioxide; tartaric acid; sodium starch glycollate; lactose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.,treatment of recurrence of anaplastic astrocytoma and glioblastoma multiforme following standard therapy.,temozolomide is also indicated as a first-line treatment for patients with advanced metastatic malignant melanoma.

TEMACCORD Australia - angielski - Department of Health (Therapeutic Goods Administration)

temaccord

accord healthcare pty ltd - temozolomide, quantity: 100 mg - capsule, hard - excipient ingredients: titanium dioxide; colloidal anhydrous silica; stearic acid; gelatin; tartaric acid; iron oxide red; purified water; sodium starch glycollate; lactose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.,treatment of recurrence of anaplastic astrocytoma and glioblastoma multiforme following standard therapy.,temozolomide is also indicated as a first-line treatment for patients with advanced metastatic malignant melanoma.

TEMACCORD Australia - angielski - Department of Health (Therapeutic Goods Administration)

temaccord

accord healthcare pty ltd - temozolomide, quantity: 20 mg - capsule, hard - excipient ingredients: titanium dioxide; colloidal anhydrous silica; sodium starch glycollate; lactose; iron oxide yellow; gelatin; tartaric acid; purified water; stearic acid; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.,treatment of recurrence of anaplastic astrocytoma and glioblastoma multiforme following standard therapy.,temozolomide is also indicated as a first-line treatment for patients with advanced metastatic malignant melanoma.

TEMACCORD Australia - angielski - Department of Health (Therapeutic Goods Administration)

temaccord

accord healthcare pty ltd - temozolomide, quantity: 5 mg - capsule, hard - excipient ingredients: titanium dioxide; iron oxide yellow; sodium starch glycollate; lactose; tartaric acid; purified water; stearic acid; gelatin; colloidal anhydrous silica; indigo carmine; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.,treatment of recurrence of anaplastic astrocytoma and glioblastoma multiforme following standard therapy.,temozolomide is also indicated as a first-line treatment for patients with advanced metastatic malignant melanoma.

TEMACCORD Australia - angielski - Department of Health (Therapeutic Goods Administration)

temaccord

accord healthcare pty ltd - temozolomide, quantity: 5 mg - capsule, hard - excipient ingredients: titanium dioxide; iron oxide yellow; sodium starch glycollate; lactose; tartaric acid; purified water; stearic acid; gelatin; colloidal anhydrous silica; indigo carmine; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.,treatment of recurrence of anaplastic astrocytoma and glioblastoma multiforme following standard therapy.,temozolomide is also indicated as a first-line treatment for patients with advanced metastatic malignant melanoma.

TEMACCORD Australia - angielski - Department of Health (Therapeutic Goods Administration)

temaccord

accord healthcare pty ltd - temozolomide, quantity: 250 mg - capsule, hard - excipient ingredients: gelatin; colloidal anhydrous silica; sodium starch glycollate; tartaric acid; stearic acid; lactose; purified water; titanium dioxide; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.,treatment of recurrence of anaplastic astrocytoma and glioblastoma multiforme following standard therapy.,temozolomide is also indicated as a first-line treatment for patients with advanced metastatic malignant melanoma.

TEMACCORD Australia - angielski - Department of Health (Therapeutic Goods Administration)

temaccord

accord healthcare pty ltd - temozolomide, quantity: 180 mg - capsule, hard - excipient ingredients: purified water; lactose; titanium dioxide; colloidal anhydrous silica; iron oxide yellow; gelatin; tartaric acid; stearic acid; sodium starch glycollate; iron oxide red; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.,treatment of recurrence of anaplastic astrocytoma and glioblastoma multiforme following standard therapy.,temozolomide is also indicated as a first-line treatment for patients with advanced metastatic malignant melanoma.